CR20140397A - Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks - Google Patents

Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks

Info

Publication number
CR20140397A
CR20140397A CR20140397A CR20140397A CR20140397A CR 20140397 A CR20140397 A CR 20140397A CR 20140397 A CR20140397 A CR 20140397A CR 20140397 A CR20140397 A CR 20140397A CR 20140397 A CR20140397 A CR 20140397A
Authority
CR
Costa Rica
Prior art keywords
oxazolidin
inhibitors
pi3ks
same
compounds
Prior art date
Application number
CR20140397A
Other languages
English (en)
Inventor
Giorgio Caravatti
Robin Alec Fairhurst
Pascal Furet
Frédéric Stauffer
Frank Hans Seiler
Heinrich Rueeger
Clive Mccarthy
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48142031&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20140397(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CR20140397A publication Critical patent/CR20140397A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

La presente invención se relaciona con compuestos de pirimidina oxazolidin- 2-ona sustituidos que actúan como inhibidores de la PI3K (fosfatidilinositol- 5 3- quinasa), así como también composiciones farmacéuticas de los mismos, métodos para sufabricación y usos para el tratamiento de condiciones, enfermedades y trastornos dependientes de PI3K. WO 2013/124826 A1.
CR20140397A 2012-02-24 2014-08-22 Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks CR20140397A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261602954P 2012-02-24 2012-02-24
US201261736707P 2012-12-13 2012-12-13
PCT/IB2013/051443 WO2013124826A1 (en) 2012-02-24 2013-02-22 Oxazolidin- 2 -one compounds and uses thereof as pi3ks inhibitors

Publications (1)

Publication Number Publication Date
CR20140397A true CR20140397A (es) 2014-10-16

Family

ID=48142031

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140397A CR20140397A (es) 2012-02-24 2014-08-22 Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks

Country Status (31)

Country Link
US (2) US8865894B2 (es)
EP (1) EP2817307B1 (es)
JP (1) JP6154404B2 (es)
KR (1) KR101640698B1 (es)
CN (1) CN104144926B (es)
AP (1) AP2014007835A0 (es)
AR (1) AR090121A1 (es)
AU (1) AU2013223713C1 (es)
BR (1) BR112014020672B1 (es)
CA (1) CA2865372A1 (es)
CO (1) CO7051028A2 (es)
CR (1) CR20140397A (es)
DO (1) DOP2014000194A (es)
EA (1) EA026031B1 (es)
ES (1) ES2598118T3 (es)
GE (1) GEP20156389B (es)
GT (1) GT201400178A (es)
HK (1) HK1199643A1 (es)
IL (1) IL233936A (es)
MX (1) MX353341B (es)
NI (1) NI201400089A (es)
NZ (1) NZ629198A (es)
PE (1) PE20142456A1 (es)
PH (1) PH12014501900A1 (es)
PL (1) PL2817307T3 (es)
PT (1) PT2817307T (es)
SG (1) SG11201404794XA (es)
TW (1) TW201339155A (es)
UY (1) UY34632A (es)
WO (1) WO2013124826A1 (es)
ZA (1) ZA201405446B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20141581A1 (es) 2011-09-27 2014-11-14 Novartis Ag 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
ES2665619T3 (es) 2013-03-14 2018-04-26 Novartis Ag 3-Pirimidin-4-il-oxazolidin-2-onas como inhibidores de IDH mutante
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
CN106103484B (zh) 2014-03-14 2021-08-20 诺华股份有限公司 针对lag-3的抗体分子及其用途
ES2719136T3 (es) 2014-03-24 2019-07-08 Novartis Ag Compuestos orgánicos de monobactam para el tratamiento de infecciones bacterianas
TW201609108A (zh) 2014-07-25 2016-03-16 諾華公司 醫藥劑型
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CU20170052A7 (es) 2014-10-14 2017-11-07 Dana Farber Cancer Inst Inc Moléculas de anticuerpo que se unen a pd-l1
WO2016064958A1 (en) 2014-10-22 2016-04-28 Bristol-Myers Squibb Company Heteroaryl substituted pyrrolotriazine amine compounds as pi3k inhibitors
EP3209664B1 (en) 2014-10-22 2020-06-03 Bristol-Myers Squibb Company Bicyclic heteroaryl amine compounds as pi3k inhibitors
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
MY190404A (en) 2015-03-10 2022-04-21 Aduro Biotech Inc Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
WO2017001658A1 (en) * 2015-07-02 2017-01-05 F. Hoffmann-La Roche Ag Benzoxazepin oxazolidinone compounds and methods of use
CN107873032B (zh) * 2015-07-02 2020-07-17 豪夫迈·罗氏有限公司 苯并氧氮杂*噁唑烷酮化合物及其使用方法
SI3317301T1 (sl) 2015-07-29 2021-10-29 Novartis Ag Kombinirane terapije, ki obsegajo molekule protitelesa na LAG-3
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
BR112018008904A2 (pt) 2015-11-03 2018-11-27 Janssen Biotech Inc anticorpos que se ligam especificamente a tim-3 e seus usos
CA3007671A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
CN109923117A (zh) * 2016-11-02 2019-06-21 柯瑞斯公司 使用具有锌结合部分的磷酸肌醇3-激酶抑制剂的联合治疗
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
JP7433910B2 (ja) 2017-06-22 2024-02-20 ノバルティス アーゲー Ｃｄ７３に対する抗体分子及びその使用
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
EP3728230A1 (en) * 2017-12-22 2020-10-28 Ravenna Pharmaceuticals, Inc. Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors
TW202015726A (zh) 2018-05-30 2020-05-01 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
CN109134558A (zh) * 2018-09-21 2019-01-04 常州方圆制药有限公司 一种提高1-N-乙基庆大霉素Cla收率的合成方法
CN109970764B (zh) * 2019-03-26 2021-11-09 上海吉奉生物科技有限公司 一种（S）-1,1,5,5-四甲基二氢恶唑并[3,4-c]恶唑-3-酮的合成方法
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法

Family Cites Families (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB581334A (en) 1943-09-29 1946-10-09 Francis Henry Swinden Curd New pyrimidine compounds
JPS4921148Y1 (es) 1970-02-07 1974-06-06
JPS4921149Y1 (es) 1970-06-27 1974-06-06
JPS4921148B1 (es) 1970-12-28 1974-05-30
JPS4921149B1 (es) 1970-12-28 1974-05-30
AT340933B (de) 1973-08-20 1978-01-10 Thomae Gmbh Dr K Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze
DE2341925A1 (de) 1973-08-20 1975-03-06 Thomae Gmbh Dr K Neue pyrimidinderivate und verfahren zu ihrer herstellung
US4261989A (en) 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
US4994386A (en) 1987-07-13 1991-02-19 Pharmacia Diagnostics, Inc. Production of HBLV virus in the HSB-2 cell line
US4929726A (en) 1988-02-09 1990-05-29 Georgia State University Foundation, Inc. Novel diazines and their method of preparation
EP0330263A1 (en) 1988-02-25 1989-08-30 Merck & Co. Inc. Piperazinylalkylpyrimidines as hypoglycemic agents
GB9012311D0 (en) 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
WO1992000970A1 (fr) 1990-07-03 1992-01-23 Mitsui Petrochemical Industries, Limited Compose de pyrimidine et sel pharmaceutiquement acceptable de ce compose
JP3145410B2 (ja) 1995-04-13 2001-03-12 大鵬薬品工業株式会社 新規な４，６−ジアリールピリミジン誘導体及びその塩
JP3734907B2 (ja) 1996-12-19 2006-01-11 富士写真フイルム株式会社 現像処理方法
AU727013B2 (en) 1997-07-24 2000-11-30 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compound and antitumor agent comprising the same as effective component
JPH11158073A (ja) 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンａ３拮抗剤
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
US6150362A (en) 1997-12-12 2000-11-21 Henkin; Jack Triazine angiogenesis inhibitors
DK0930302T3 (da) 1998-01-16 2003-07-21 Hoffmann La Roche Benzosulfonderivater
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
DE69919707T2 (de) 1998-06-19 2005-09-01 Chiron Corp., Emeryville Glycogen synthase kinase 3 inhibitoren
US6495558B1 (en) 1999-01-22 2002-12-17 Amgen Inc. Kinase inhibitors
AU768201B2 (en) 1999-01-22 2003-12-04 Amgen, Inc. Kinase inhibitors
AU6605200A (en) 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
CA2376951A1 (en) 1999-06-30 2001-01-04 Peter J. Sinclair Src kinase inhibitor compounds
US6498165B1 (en) 1999-06-30 2002-12-24 Merck & Co., Inc. Src kinase inhibitor compounds
WO2001005783A1 (en) 1999-07-15 2001-01-25 Pharmacopeia, Inc. Bradykinin b1 receptor antagonists
JP2001089452A (ja) 1999-09-22 2001-04-03 Sankyo Co Ltd ピリミジン誘導体
WO2001060816A1 (en) 2000-02-17 2001-08-23 Amgen Inc. Kinase inhibitors
EP1274705A1 (en) 2000-03-29 2003-01-15 Cyclacel Limited 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
CN100345830C (zh) 2000-04-27 2007-10-31 安斯泰来制药有限公司 稠合杂芳基衍生物
WO2001083460A1 (fr) 2000-04-28 2001-11-08 Tanabe Seiyaku Co., Ltd. Composes cycliques
WO2002000647A1 (en) 2000-06-23 2002-01-03 Bristol-Myers Squibb Pharma Company Heteroaryl-phenyl substituted factor xa inhibitors
AU9502601A (en) 2000-09-06 2002-03-22 Chiron Corp Inhibitors of glycogen synthase kinase 3
AU2001292670A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
SE0004053D0 (sv) 2000-11-06 2000-11-06 Astrazeneca Ab N-type calcium channel antagonists for the treatment of pain
BR0116411A (pt) 2000-12-21 2003-11-11 Vertex Pharma Compostos de pirazol úteis como inibidores de proteìna cinase
EP1363890A4 (en) 2001-02-07 2009-06-10 Ore Pharmaceuticals Inc MELANOCORTIN-4-RECEPTOR BINDING COMPOUNDS AND METHOD FOR THEIR APPLICATION
AU2002258400A1 (en) 2001-02-16 2002-08-28 Tularik Inc. Methods of using pyrimidine-based antiviral agents
JP2004531571A (ja) 2001-05-25 2004-10-14 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド サイトカイン生産のインヒビターとしてのカルバメート及びオキサミド化合物
JP2005500294A (ja) 2001-06-19 2005-01-06 ブリストル−マイヤーズ　スクイブ　カンパニー ホスホジエステラーゼ７に対するピリミジン阻害剤
US6603000B2 (en) 2001-07-11 2003-08-05 Boehringer Ingelheim Pharmaceuticals, Inc. Synthesis for heteroarylamine compounds
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
EP1485381B8 (en) 2002-03-15 2010-05-12 Vertex Pharmaceuticals Incorporated Azolylaminoazine as inhibitors of protein kinases
WO2003078423A1 (en) 2002-03-15 2003-09-25 Vertex Pharmaceuticals, Inc. Compositions useful as inhibitors of protein kinases
AU2003218215A1 (en) 2002-03-15 2003-09-29 Vertex Pharmaceuticals, Inc. Azolylaminoazines as inhibitors of protein kinases
DE60332433D1 (de) 2002-03-15 2010-06-17 Vertex Pharma Azolylaminoazine als proteinkinasehemmer
US20040082627A1 (en) 2002-06-21 2004-04-29 Darrow James W. Certain aromatic monocycles as kinase modulators
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
AU2003275242B2 (en) 2002-09-27 2010-03-04 Merck Sharp & Dohme Corp. Substituted pyrimidines
AU2003288925A1 (en) 2002-10-08 2004-05-04 Massachusetts Institute Of Technology Compounds for modulation of cholesterol transport
US7223870B2 (en) 2002-11-01 2007-05-29 Pfizer Inc. Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
AU2003295776B2 (en) 2002-11-21 2011-05-12 Novartis Vaccines And Diagnostics, Inc. 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer
EP1608622A4 (en) 2003-03-24 2009-04-01 Merck & Co Inc BIARYLSUBSTITUTED 6-LOW HETEROCYCLES AS SODIUM CHANNEL BLOCKERS
US20050014753A1 (en) 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
EP1610774A4 (en) 2003-04-09 2008-07-16 Exelixis Inc TIE-2 MODULATORS AND METHODS OF USE
WO2005002514A2 (en) 2003-06-13 2005-01-13 Echelon Biosciences Incorporated Compounds having inhibitibe activity of phosphatidylinositol 3-kinase and methods of use thereof
CA2531490A1 (en) 2003-07-15 2005-02-03 Neurogen Corporation Substituted pyrimidin-4-ylamina analogues as vanilloid receptor ligands
AU2004257289A1 (en) 2003-07-16 2005-01-27 Neurogen Corporation Biaryl piperazinyl-pyridine analogues
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
AU2005232745A1 (en) 2004-04-13 2005-10-27 Astellas Pharma Inc. Polycyclic pyrimidines as potassium ion channel modulators
GB0415365D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
GB0415364D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
MY145822A (en) 2004-08-13 2012-04-30 Neurogen Corp Substituted biaryl piperazinyl-pyridine analogues
EP1827434B1 (en) 2004-11-30 2014-01-15 Amgen Inc. Quinolines and quinazoline analogs and their use as medicaments for treating cancer
JP2008523156A (ja) 2004-12-13 2008-07-03 ニューロジェン・コーポレーション 置換ビアリール類縁体
CN101080228A (zh) 2004-12-13 2007-11-28 神经能质公司 哌嗪基－吡啶类似物
US7300931B2 (en) 2004-12-28 2007-11-27 Kinex Pharmaceuticals, Llc Compositions for treating cell proliferation disorders
AU2006206246A1 (en) 2005-01-19 2006-07-27 Neurogen Corporation Heteroaryl substituted piperazinyl-pyridine analogues
KR20070108916A (ko) 2005-02-25 2007-11-13 쿠도스 파마슈티칼스 리미티드 Ｍｔｏｒ 억제제로서 작용하는 하이드라지노메틸,하이드라조노메틸 및 5-원 복소환 화합물 및 이의항암제로서의 용도
CA2606288A1 (en) 2005-04-18 2006-10-26 Neurogen Corporation Subtituted heteroaryl cb1 antagonists
BRPI0611707A2 (pt) 2005-06-29 2012-04-24 Compumedics Ltd conjunto de sensor com ponte condutiva
GB2431156A (en) 2005-10-11 2007-04-18 Piramed Ltd 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
EP1979325A1 (en) 2006-01-11 2008-10-15 AstraZeneca AB Morpholino pyrimidine derivatives and their use in therapy
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
WO2007120897A2 (en) * 2006-04-13 2007-10-25 The Trustees Of Columbia University In The City Of New York Compositions and intraluminal devices for inhibiting vascular stenosis
WO2008080937A1 (en) 2006-12-28 2008-07-10 Basf Se 2-substituted pyrimidines i in therapy
CA2675558A1 (en) 2007-02-06 2008-08-14 Novartis Ag Pi 3-kinase inhibitors and methods of their use
US7957951B2 (en) 2007-03-16 2011-06-07 Robert Bosch Gmbh Address translation system for use in a simulation environment
AR067478A1 (es) 2007-07-09 2009-10-14 Astrazeneca Ab Compuestos derivados de morfolina pirimidina
WO2009066084A1 (en) * 2007-11-21 2009-05-28 F. Hoffmann-La Roche Ag 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors
AU2009221164B2 (en) 2008-03-05 2012-07-26 Novartis Ag Use of pyrimidine derivatives for the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members
BRPI0909082A2 (pt) 2008-03-26 2019-02-26 Novartis Ag imidazoquinolinas e derivados de pirimidina como moduladores potentes de processos angiogênicos acionados por vegf
WO2009120094A2 (en) 2008-03-27 2009-10-01 Auckland Uniservices Limited Substituted pyrimidines and triazines and their use in cancer therapy
US8575338B2 (en) 2008-04-09 2013-11-05 Mitsubishi Tanabe Pharma Corporation Pyrimidine, pyridine and triazine derivatives as maxi-K channel openers
GB0815369D0 (en) 2008-08-22 2008-10-01 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
EP2349275B1 (en) 2008-10-31 2017-03-08 Novartis AG Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor.
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
WO2010068863A2 (en) 2008-12-12 2010-06-17 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
JP5747440B2 (ja) 2009-02-06 2015-07-15 住友化学株式会社 ヒドラジド化合物及びその有害生物防除用途
AU2010211672B2 (en) 2009-02-06 2016-08-04 Nippon Shinyaku Co., Ltd. Aminopyrazine derivative and medicine
AU2010223919B2 (en) 2009-03-13 2016-03-31 Les Laboratoires Servier Methods and compositions for cell-proliferation-related disorders
WO2010120994A2 (en) 2009-04-17 2010-10-21 Wyeth Llc Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
RU2011151603A (ru) 2009-05-19 2013-06-27 ДАУ АГРОСАЙЕНСИЗ ЭлЭсСи Соединения и способы борьбы с грибами
EP2451802A1 (en) 2009-07-07 2012-05-16 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
WO2011017296A1 (en) 2009-08-04 2011-02-10 Schering Corporation 4, 5, 6-trisubstituted pyrimidine derivatives as factor ixa inhibitors
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
CA2773848A1 (en) 2009-09-09 2011-03-17 Avila Therapeutics, Inc. Pi3 kinase inhibitors and uses thereof
ES2642109T3 (es) 2009-12-09 2017-11-15 Agios Pharmaceuticals, Inc. Compuestos terapéuticamente activos para su uso en el tratamiento de cáncer caracterizados por tener una mutación de IDH
GB201004200D0 (en) 2010-03-15 2010-04-28 Univ Basel Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
US20130109643A1 (en) 2010-05-10 2013-05-02 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
ES2704862T3 (es) 2010-07-16 2019-03-20 Agios Pharmaceuticals Inc Composiciones terapéuticamente activas y su método de uso
KR20130119928A (ko) 2010-10-01 2013-11-01 노파르티스 아게 피리미딘 유도체의 제조 방법
LT2629776T (lt) 2010-10-18 2017-11-10 Cerenis Therapeutics Holding Sa Junginiai, kompozicijos ir būdai, tinkami cholesterolio mobilizavimui
GB201106829D0 (en) 2011-04-21 2011-06-01 Proximagen Ltd Heterocyclic compounds
CA2826387A1 (en) 2011-02-11 2012-08-16 Dana Farber Cancer Institute, Inc. Method of inhibiting hamartoma tumor cells
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN103764130A (zh) 2011-09-01 2014-04-30 诺华股份有限公司 用于治疗骨癌或者预防原发性癌细胞转移性播散入骨中的pi3k抑制剂
PE20141581A1 (es) 2011-09-27 2014-11-14 Novartis Ag 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
CA2851082A1 (en) 2011-10-06 2013-04-11 Merck Sharp & Dohme Corp. 1,3-substituted azetidine pde10 inhibitors
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
JP6381523B2 (ja) 2012-05-16 2018-08-29 ノバルティス アーゲー Ｐｉ−３キナーゼ阻害剤の投与レジメン
CN104349771A (zh) 2012-06-06 2015-02-11 诺华股份有限公司 用于***疾病的17α-羟化酶(C17,20-裂解酶)抑制剂和特定PI-3K抑制剂的组合
CN105050623B (zh) 2012-08-16 2018-06-12 诺华股份有限公司 Pi3k抑制剂和c-met抑制剂的组合
WO2014064058A1 (en) 2012-10-23 2014-05-01 Novartis Ag Improved process for manufacturing 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
ES2665619T3 (es) 2013-03-14 2018-04-26 Novartis Ag 3-Pirimidin-4-il-oxazolidin-2-onas como inhibidores de IDH mutante
CN103483345B (zh) 2013-09-25 2016-07-06 中山大学 Pi3k激酶抑制剂、包含其的药物组合物及其应用
CN103694218B (zh) 2013-12-05 2016-04-27 中山大学 嘧啶化合物、pi3k抑制剂、包含pi3k抑制剂的药物组合物及应用

Also Published As

Publication number Publication date
PL2817307T3 (pl) 2017-01-31
EA026031B1 (ru) 2017-02-28
KR20140117581A (ko) 2014-10-07
HK1199643A1 (en) 2015-07-10
NZ629198A (en) 2015-10-30
GT201400178A (es) 2015-06-02
US8865894B2 (en) 2014-10-21
AU2013223713A1 (en) 2014-09-11
US20130225574A1 (en) 2013-08-29
EA201491579A1 (ru) 2015-06-30
JP2015508096A (ja) 2015-03-16
PT2817307T (pt) 2016-10-25
ES2598118T3 (es) 2017-01-25
WO2013124826A1 (en) 2013-08-29
CA2865372A1 (en) 2013-08-29
BR112014020672B1 (pt) 2020-09-01
UY34632A (es) 2013-05-31
PE20142456A1 (es) 2015-01-14
EP2817307B1 (en) 2016-07-13
AR090121A1 (es) 2014-10-22
CN104144926A (zh) 2014-11-12
SG11201404794XA (en) 2014-09-26
TW201339155A (zh) 2013-10-01
MX2014010141A (es) 2014-09-08
EP2817307A1 (en) 2014-12-31
KR101640698B1 (ko) 2016-07-18
CN104144926B (zh) 2016-10-26
JP6154404B2 (ja) 2017-06-28
DOP2014000194A (es) 2014-10-15
AU2013223713C1 (en) 2016-01-07
ZA201405446B (en) 2015-10-28
US9458177B2 (en) 2016-10-04
IL233936A (en) 2016-04-21
NI201400089A (es) 2015-04-13
MX353341B (es) 2018-01-08
PH12014501900A1 (en) 2014-11-24
GEP20156389B (en) 2015-10-26
AU2013223713B2 (en) 2014-12-11
AP2014007835A0 (en) 2014-07-31
US20140378450A1 (en) 2014-12-25
CO7051028A2 (es) 2014-09-10

Similar Documents

Publication Publication Date Title
CR20140397A (es) Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks
CR20150248A (es) Derivados de oxazolidin-2-ona-pirimidina
CL2017002650A1 (es) Compuestos novedosos
SV2015005066A (es) Compuestos de biaril-amida como inhibidores de cinasa
CR20150255A (es) Derivados triciclicos fusionados de tiofeno como inhibidores de jak
CR20150425A (es) Compuestos azabencimidazol como inhibidores de las isozimas pde4, para el tratamiento del sistema nervioso central y otros desórdenes
TR201901886T4 (tr) DNA-PK inhibitörleri.
PH12016501160A1 (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
DOP2012000257A (es) Derivados del acido 1-amino-2-ciclopropiletilboronico
CL2015000956A1 (es) Compuestos derivados de pirrolotriazinona como inhibidores de pi3k; composicion farmaceutica que los comprende; combinacion farmaceutica; uso para tratar enfermedades respiratorias, autoinmunes, trastornos neurologicos, cardiovasculares, metabolicos, entre otros.
DOP2014000253A (es) Inhibidores del nampt
CR20130464A (es) Inhibidores sustituidos de acetil-coa carboxilasa
GT201400242A (es) "nuevos compuestos de pirazol"
CL2017000827A1 (es) Inhibidores de aldosterona sintasa
CU20140102A7 (es) Compuestos de oxazolidin-2- ona y usos de los mismos como inhibidores de la p13ks
AR122753A2 (es) Inhibidores selectivos de proteínas cinasas delta pi3k, composiciones farmacéuticas, usos, y métodos de tratamiento y/o prevención de las enfermedades o trastornos mediados por cinasas
ECSP15021681A (es) Derivados tricíclicos fusionados de tiofeno como inhibidores de jak